Fibromialgia

  1. Carabot, F. 1
  2. Valadés Periáñez, M.T. 2
  3. Álvarez Mon, M.Á 3
  4. Vidal Marcos, A. 4
  1. 1 Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, Madrid, España Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España Departamento de Anestesia y Terapéutica del Dolor, Clínica Juaneda Miramar, Palma, Mallorca, España
  2. 2 Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, Madrid, España Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España
  3. 3 Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, Madrid, España Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España Departamento de Psiquiatría y Salud Mental, Hospital Universitario Infanta Leonor, Madrid, España
  4. 4 Departamento de Farmacología y Toxicología, Universidad Complutense de Madrid, Madrid, España Unidad del Dolor, Hospital Quirónsalud Sur, Alcorcón, Madrid, España
Show affiliations +
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2023

Issue Title: Actualidad clínico-terapéutica (IV)

Series: 13

Issue: 92

Pages: 5427-5442

Type: Article

DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Fibromyalgia (FM) is a disease whose main feature is chronic generalized pain of idiopathic origin as well as fatigue, sleep disorders, and neurological symptoms. Despite its high prevalence, FM continues to pose diagnostic and therapeutic challenges for health professionals. FM develops due to multiple unique factors that include a genetic predisposition, personal experiences, emotional and cognitive factors, the mind-body relationship, and the biopsychological ability to cope with stress. Its variable nature and symptoms together with associated comorbidities make it difficult to reach an early diagnosis. The diagnostic criteria are still a matter of debate and the lack of specific tests and pathognomonic pathologies of the disease contribute to the lack of precise diagnosis. Given that the pathogenesis and continuation of this condition involve multiple components, a multimodal treatment approach is required. Despite the availability of various treatments, its management remains a challenge. An effective treatment approach should be personalized and multidisciplinary. Goals should be realistic and prioritize maintaining or improving function, improving quality of life, and managing symptoms.

Bibliographic References

  • Aloush V, Niv D, Ablin JN, Yaish I, Elkayam O, Elkana O. Good pain, bad pain: illness perception and physician attitudes towards rheumatoid arthritis and fibromyalgia patients. Clin Exp Rheumatol. 2021;39(3):54-60.
  • Giorgi V, Sirotti S, Romano ME, Marotto D, Ablin JN, Salaffi F. Fibromyalgia: one year in review 2022. Clin Exp Rheumatol. 2022;40(6):1065-72.
  • Sarzi Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645-60.
  • Casale R, Sarzi Puttini P, Botto R, Alciati A, Batticciotto A, Marotto D. Fibromyalgia and the concept of resilience. Clin Exp Rheumatol. 2019;37Suppl116(1):10513.
  • Jones GT, Atzeni F, Beasley M, Flüß E, Sarzi Puttini P, Macfarlane GJ. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015;67(2):568-75.
  • Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther. 2009;11(3):117.
  • Lacasse A, Bourgault P, Choinière M. Fibromyalgia-related costs and loss of productivity: a substantial societal burden. BMC Musculoskelet Disord. 2016;17(1):168.
  • Alciati A, Sgiarovello P, Atzeni F, Sarzi Puttini P. Psychiatric problems in fibromyalgia: clinical and neurobiological links between mood disorders and fibromyalgia. Reumatismo. 2012;64(4):268-74.
  • Sarzi Puttini P, Atzeni F, Di Franco M, Buskila D, Alciati A, Giacomelli C. Dysfunctional syndromes and fibromyalgia: a 2012 critical digest. Clin Exp Rheumatol. 2012;30(6)Suppl74:143-51.
  • Smith HS, Harris RE, Clauw DJ. Fibromyalgia. En: Benzon HT, Raja SN, Molly RE, Liu SS, Fishman SM, editors. Essentials of pain medicine. 3rd ed. Philadelphia: Elsevier; 2011. p. 345-50.
  • Chinn S, Caldwell W, Gritsenko K. Fibromyalgia pathogenesis and treatment options update. Curr Pain Headache Rep. 2016;20(4):25.
  • Ghavidel Parsa B, Bidari A, Atrkarroushan Z, Khosousi M. Implication of the nociplastic features for clinical diagnosis of fibromyalgia: Development of the preliminary nociplastic‐based fibromyalgia features tool. ACR Open Rheumatol. 2022;4(3):260-8.
  • Littlejohn G. Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. Nat Rev Rheumatol. 2015;11(11):639-48.
  • Bair MJ, Krebs EE. Fibromyalgia. Ann Intern Med. 2020;172(5):ITC33.
  • Choy EHS. The role of sleep in pain and fibromyalgia. Nat Rev Rheumatol. 2015;11(9):513-20.
  • Harris RE, Clauw DJ. How do we know that the pain in fibromyalgia is “real”? Curr Pain Headache Rep. 2006;10(6):403-7.
  • Singh R, Rai NK, Rastogi A, Endukuru C, Joshi A, Mishra SS. Impact of sleep disturbances and autonomic dysfunction on the quality of life of patients with fibromyalgia. J Basic Clin Physiol Pharmacol. 2021;32(6):10219.
  • Jones KD, Horak FB, Winters Stone K, Irvine JM, Bennett RM. Fibromyalgia Is associated with impaired balance and falls. JCR. 2009;15(1):16-21.
  • Dreyer L, Kendall S, Danneskiold Samsøe B, Bartels EM, Bliddal H. Mortality in a cohort of Danish patients with fibromyalgia: Increased frequency of suicide. Arthritis Rheum. 2010;62(10):3101-8.
  • Clauw DJ. Fibromyalgia. JAMA. 2014;311(15):1547.
  • Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-29.
  • Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL. AAPT diagnostic criteria for fibromyalgia. J Pain. 2019;20(6):611-28.
  • Hsu W, Han D, Ku W, Chao Y, Chen C, Lin Y. Metabolomic and proteomic characterization of sng and pain phenotypes in fibromyalgia. Eur J Pain. 2022;26(2):445-62.
  • Alves MVS, Maciel LIL, Ramalho RRF, Lima LAS, Vaz BG, Morais CLM. Multivariate classification techniques and mass spectrometry as a tool in the screening of patients with fibromyalgia. Sci Rep. 2021;11(1):22625.
  • Hadler NM. “Fibromyalgia” and the medicalization of misery. J Rheumatol. 2003;30(8):1668-70.
  • Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-28.
  • Kundakci B, Kaur J, Goh SL, Hall M, Doherty M, Zhang W. Efficacy of nonpharmacological interventions for individual features of fibromyalgia: a systematic review and meta-analysis of randomised controlled trials. Pain. 2022;163(8):1432-45.
  • Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N. Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia. JAMA Intern Med. 2021;181(1):104.
  • Argaman Y, Granovsky Y, Sprecher E, Sinai A, Yarnitsky D, Weissman Fogel I. Clinical effects of repetitive transcranial magnetic stimulation of the motor cortex are associated with changes in resting-state functional connectivity in patients with fibromyalgia syndrome. J Pain. 2022;23(4):595-615.
  • Ceballos Laita L, Mingo Gómez MT, Estébanez de Miguel E, Bueno Gracia E, Navas Cámara FJ, Verde Rello Z. Does the addition of pain neurophysiology education to a therapeutic exercise program improve physical function in women with fibromyalgia syndrome? Secondary analysis of a randomized controlled trial. J Clin Med. 2021;10(11):2518.
  • Sousa M, Oliveira R, Brito JP, Martins AD, Moutão J, Alves S. Effects of combined training programs in individuals with fibromyalgia: A systematic review. Healthcare. 2023;11(12):1708.
  • Theadom A, Cropley M, Smith HE, Feigin VL, McPherson K. Mind and body therapy for fibromyalgia. Cochrane Database Syst Rev. 2015;2015(4):CD001980.
  • Alberti FF, Becker MW, Blatt CR, Ziegelmann PK, da Silva Dal Pizzol T, Pilger D. Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network metaanalysis. Clin Rheumatol. 2022;41(7):1965-78.
  • Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Medicine. 2007;8Suppl2:S63-S74.
  • Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419-31.
  • Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;(10):CD010782.
  • Derry S, Wiffen PJ, Häuser W, Mücke M, Tölle TR, Bell RF. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database Syst Rev. 2017;3(3):CD012332.
  • Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid use in fibromyalgia. Mayo Clin Proc. 2016;91(5):640-8.
  • Jackson D, Singh S, Zhang James Y, Faraone S, Johnson B. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front Psychiatry. 2021;12:593842.
  • Fitzcharles MA, Rampakakis E, Sampalis JS, Shir Y, Cohen M, Starr M. Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. Clin Exp Rheumatol. 2021;39(3):115-9.
  • Russell JI, Holman AJ, Swick TJ, Alvarez Horine S, Wang GY, Guinta D. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: Results from a 14-week, randomized, doubleblind, placebo-controlled study. Pain. 2011;152(5):1007-17.
  • Staud R. Sodium oxybate for the treatment of fibromyalgia. Expert Opin Pharmacother. 2011;12(11):1789-98.
  • White HD, Robinson TD. A novel use for testosterone to treat central sensitization of chronic pain in fibromyalgia patients. Int Immunopharmacol. 2015;27(2):244-8.
  • Corriger A, Voute M, Lambert C, Pereira B, Pickering G. Ketamine for refractory chronic pain: a 1-year follow-up study. Pain. 2022;163(4):690701.
  • de Carvalho JF, Skare TL. Lidocaine in fibromyalgia: A systematic review. World J Psychiatry. 2022;12(4):615-22.
Data source: Dialnet